STARTVAC® (HIPRA) is a polyvalent mastitis vaccine, directed against both enterobacterial and staphylococcal species, that has been registered for use in the European Union and in many other countries worldwide. The STARTVAC® formulation is based in the inactivated Escherichia coli J5 strain and a Staphylococcus aureus bacteria containing the exopolysaccharide Poly-N-acetyl β-1,6 glucosamine (PNAG) involved the biofilm phenotype of the bacteria. The objective of this study was to analyse the reactivity of the antibodies induced by the STARTVAC® vaccine against S. aureus and E. coli bovine mastitis isolates from different areas of Japan and Europe.
Antigenicity differences between Japanese and European Staphylococcus aureus and Escherichia coli bovine mastitis isolates
Publications
Cattle
This study indicates that S. aureus and E. coli bovine mastitis isolates from Japan and Europe, present common surface antigens recognized by antibodies induced with STARTVAC® vaccination.